
Maximiliano Gelli
@gellimaximilia1
Surgical oncology HPB surgery MD, PhD
ID: 1212374977527238656
01-01-2020 14:08:29
17 Tweet
44 Followers
105 Following





An amazing #EuroPCR2021 Terrific sessions & interactive education. Great experience, all the ICPS team was delighted to participate! See you in 2022! Best of the EuroPCR livestreamed Courses bit.ly/3v3Wjg2 PCRonline 🫀



#ASCO2023 Proud to present PACHA trial on behalf DIANE GOERE David Malka @DucreuxMichel and other investigators 🙏 🔎 Postop HAI vs IV Ox after resection of ≥ 4 CRLM ✅ HAI ↗️ hepatic RFS 📌 Trend to increase DFS and OS ⚠️ higher but manageable Tox ❗️HAI Ox don’t need pump⛽️



@Jfhod2024 📣Positive result from PACHA 01 phase 2 RCT 📣 🔍HAI vs IV oxaliplatin after resection 4 or more CRLM 🔎 ‼️ HAI improves hepatic RFS (HR 0.63) 🧨but also DFS and trend for OS 🙌🙌 👉Phase 3 study soon ! Prodigè Group Gustave Roussy

New The Lancet - Adam et al - Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet trial) thelancet.com/journals/lance… #CRCSM #LiverTwitter


Liver transplantation + CTx vs CTx in unresectable CRC liver metastases 🔎TransMet randomised trial The Lancet doi.org/10.1016/S0140-… 👉5-yr OS: 56.6 vs 12.6% 👉Recurrence after LTx: 72% 🧐Impressive study, impressive results ❗️LTx valid option in highly selected pts ESMO - Eur. Oncology


🚨 Thrilled to share the TRANSMET results in The Lancet. 🙏 Grateful to the TRANSMET Collaborative group, patients, and their families! 🙌 Special thanks to rene adam Centre Hépato-Biliaire, Hôpital Paul Brousse for bringing me on this incredible adventure 10 years ago #CRLM ACHBT Gustave Roussy アベマ


🏆 Palmarès 2024 des hôpitaux et cliniques du Point 🏆 Cette année encore, Gustave Roussy confirme sa position de leader en #oncologie en France 🇫🇷. 🔹 1ᵉʳ dans la prise en charge des cancers ORL depuis 2014 ; 🔹 1ᵉʳ dans la prise en charge des tumeurs du cerveau de l'enfant


Paper 2: The #TRANSMET study shows liver transplantation + chemo improves 5-year survival (56.6%) vs chemo alone (12.6%) for unresectable colorectal liver metastases. A potential game-changer in colorectal liver metastases! The Lancet Oncology thelancet.com/journals/lance…


🎥 L'essentiel de l'#ASCO25 vu par Gustave Roussy. Après le congrès annuel de l'ASCO, les médecins-chercheurs de l'institut se sont réunis pour décrypter les avancées des dernières recherches en oncologie. 👉 Cette année, les experts de Gustave Roussy ont participé à plus à
